Stem Cell Transplant and Cellular Therapy - Autologous

Multiple Myeloma
- IRB # 17699: Phase III 2-part randomized study comparing G-CSF + BL-8040 with G-CSF + placebo for mobilization before autologous stem cell transplant
- IRB # 9398: Phase III comparing lenalidamide, bortezomib, dexamethasone (RVD) to High Dose treatment with peripheral stem cell transplant

Mantle Cell Lymphoma
- IRB # 18286: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

AML and MDS
- IRB # 15993: Phase 1 relapsed or refractory myeloid neoplasms. Must express HLA-A2.01 and PRAME

DLBCL
- IRB # 16830: Alliance/CTN Ibrutinib for ABC subtype
- IRB # 18449: A Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adults with High-Risk, Transplant-Eligible, Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)

CAR-T Treatment
- IRB # 18855: A Phase IB, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination with Ibrutinib in Adult Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- IRB # 18600: Study Evaluating the Safety and Efficacy of JCARH125 in Subjects with Relapsed or Refractory Multiple Myeloma (EVOLVE)

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php